| First Author | Shi X | Year | 2014 |
| Journal | Int J Clin Exp Pathol | Volume | 7 |
| Issue | 2 | Pages | 509-20 |
| PubMed ID | 24551271 | Mgi Jnum | J:288348 |
| Mgi Id | MGI:6431189 | Citation | Shi X, et al. (2014) Tim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 production. Int J Clin Exp Pathol 7(2):509-20 |
| abstractText | Previously, we demonstrated that Tim-1-Fc prevents acute cardiac graft rejection by inhibiting Th1 response. In the present report, we tackled the impact of Tim-1-Fc on Th17 cells in a model of cardiac chronic rejection. Administration of Tim-1-Fc did not result in a detectable impact on innate immunity and regulatory T cells, while it provided protection for Bm12-derive cardiac grafts against chronic rejection in B6 recipients, as manifested by the reduction of inflammatory infiltration along with less severity of vasculopathy. Studies in T-bet(-/-) recipients by implanting Bm12-derived cardiac grafts further revealed that Tim-1-Fc significantly protected cardiac grafts from chronic rejection along with attenuated production of IL-17 producing T cells. Depletion of CD4 and CD8 T cells or blockade of IL-17 in T-bet(-/-) recipients demonstrated that Tim-1-Fc selectively suppresses Th17 differentiation along with attenuated IL-17 secretion. Together, our data suggest that Tim-1-Fc protects cardiac grafts from chronic rejection by suppressing CD4 Th17 development and functionality. Therefore, Tim-1-Fc might be a potential immunosuppressive agent in the setting of cardiac transplantation. |
